INTRODUCTION
Photochemotherapy using long wave high intensity ultraviolet rays and oral psoralen (PUVA) is an effective although palliative treatment in chronic psoriasis I with therapeutic efficacy comparable to dithranol application.2 Patient acceptance is high owing to minimal use of ointments, but potential long-term hazards have not been clearly delineated. It is widely recognised that the possibility of premature ageing, skin cancers, cataract formation, pigmentary changes and alteration in the immune system are potential risks associated with PUVA therapy. 3 It is often necessary to use therapy continuously with consequent high total cumulative doses of long wave ultraviolet rays (UVA). The problem of finding safe and effective treatment for chronic plaque psoriasis remains, and dermatologists are constantly striving to find an effective but safe protocol for administering PUVA therapy. There is no general agreement as to whether a maintenance regimen should be used or, if a maintenance regimen is used, what form is effective with minimum exposure to UVA. Since PUVA therapy became available in our skin unit we have been revising our treatment protocol in the light of available data on PUVA therapy. There are only a few published reports concerning the remission period following PUVA therapy and its relationship to total UVA exposure. By constantly revising the treatment protocol, it became possible to compare various regimes of PUVA therapy administered to our patients with psoriasis. The object of this retrospective study is to compare groups of patients who had maintenance PUVA with a group who had received no maintenance therapy with PUVA and to relate the total UVA exposure to the length of remission period.
PATIENTS
Only patients with chronic stable plaque psoriasis were selected for the study. All patients were assessed according to already published criteria2 prior to starting PUVA therapy. Full clinical examination and laboratory tests (haemoglobin, total white cell count, platelet count, serum bilirubin, alkaline phosphatase, aspartate and alanine transaminase, gamma gluteryl transpeptidase and blood urea) were carried out to exclude co-existing medical problems. The laboratory tests were repeated once during the treatment and at the completion of PUVA therapy in each case. A detailed ophthalmological examination was performed before starting PUVA therapy and after the therapy in all cases. Only those with type 11 skin were included in the study. All had extensive involvement of their skin with psoriasis, more than 10 % of their body surface. Age ranged from 18 to 70 years, mean 37 years. Three groups of 30 patients matched for age and sex were analysed, depending upon the maintenance regimen of PUVA therapy used.
PUVA THERAPY All patients were treated with PUVA three times weekly until their psoriasis resolved completely, and thereafter according to the maintenance regimen described below. The drug 8-methoxypsoralen was used in a dosage of 0.6 mg/kg body weight, given two hours before the UVA exposure. The initial dose of UVA was 1.5 joules/cm2, increasing by 0.5 to 1.00 joules/cm2 every 3-4 treatments according to individual needs, using a Waldman 'PUVA 4000' unit. Clinical clearance was considered to have occurred when the psoriatic lesions had flattened completely, both visually and on palpation. The time taken to clear the psoriasis ranged from 4 to 10 weeks. Group L. After clearance of psoriasis this group was given weekly maintenance treatment with progressive lengthening of the interval between treatments finishing with one treatment every 3-4 weeks. This period of maintenance PUVA was approximately 4 months. At this stage PUVA therapy was stopped. Group 11. After the clearing regimen, patients were treated once every 3 weeks with maintenance PUVA. Duration of maintenance varied from 6 to 7 months. Group IIL. After the clearing regimen, no maintenance treatment was given. All patients were reviewed at 2 months after stopping PUVA therapy and thereafter if they relapsed. A relapse was considered -to-have occurred with the development of new lesions of psoriasis involving about 5 % of the body surface. Remission time was calculated from the time clearance therapy was stopped until relapse. Patients were observed for a period ranging from 2 months to 24 months. Statistical analysis was performed using the paired t test.4
RESULTS
The number of treatments to clear psoriasis in each group was the same (Table) . The three groups had similar durations of remission. No difference was observed between groups either in the mean total number of treatments needed to clear The Ulster Medical Journal psoriasis or in the length of remission achieved. Group III received a lower dose of UVA to achieve the same duration of remission than Groups I and II (p < 0.0005), and Group 11 received less than Group I (p < 0.05). 
